Renowned Gastrointestinal Radiation Oncologist Hired to Lead Clinical Cancer Research at Mount Sinai
February 19th 2020Karyn Aalami Goodman, MD, MS, an internationally recognized expert on gastrointestinal cancers, has joined the Icahn School of Medicine at Mount Sinai as Associate Director for Clinical Research at The Tisch Cancer Institute. She is also Professor and Vice Chair for Research and Quality in the Department of Radiation Oncology.
Dr. Oh on Targeted Treatment in Metastatic Castration-Resistant Prostate Cancer
February 8th 2020William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, and deputy director of The Tisch Cancer Institute, discusses targeted treatment in metastatic castration-resistant prostate cancer (mCRPC).
Talking Tumors: Filling Data Gaps in Multiple Myeloma
November 14th 2019We sat down with Ajai Chari, MD, and Sundar Jagannath, MD, both of Mount Sinai Hospital, to provide insight on controversial, but critical, questions regarding the merits of quadruplet versus triplet therapy in the newly diagnosed setting, the optimal maintenance approach in high-risk patients, and the data in support of and against initiating treatment in patients with smoldering multiple myeloma.
Dr. Chari on the Use of Frontline Daratumumab in Transplant-Eligible Patients With Myeloma
August 8th 2019Ajai Chari, MD, associate professor, hematology and medical oncology, Mount Sinai Hospital, discusses the use of frontline daratumumab (Darzalex) in transplant-eligible patients with multiple myeloma.
Dr. Galsky on the HCRN GU14-182 Study Results in Urothelial Cancer
August 6th 2019Matthew D. Galsky, MD, director, Genitourinary Medical Oncology, The Tisch Cancer Institute, Mount Sinai Hospital, discusses results from the HCRN GU14-182 study, which examined maintenance pembrolizumab versus placebo in patients with metastatic urothelial cancer.
Dr. Llovet on Efficacy of Namodenoson in Child-Pugh B HCC
August 6th 2019Josep M. Llovet, MD, discusses a phase II, double-blind, placebo-controlled trial examining the efficacy and safety of namodenoson, an A3 adenosine receptor agonist, as a second-line treatment for patients with Child-Pugh B advanced hepatocellular carcinoma.